MatthewDavidTroyerMD

Clinical Trials

• Study to Evaluate DNL201 in Subjects With Parkinson's Disease Start of enrollment: 2018 Dec 04

  Completed

  Phase 1

• Study to Evaluate DNL747 in Subjects With Alzheimer's Disease Start of enrollment: 2019 Feb 13

  Completed

  Phase 1

• Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis Start of enrollment: 2018 Dec 14

  Terminated

  Phase 1

• A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome Start of enrollment: 2019 Oct 23

  Completed

• Study to Evaluate DNL151 in Subjects With Parkinson's Disease Start of enrollment: 2019 Jul 23

  Completed

  Phase 1

• A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome Start of enrollment: 2020 Jul 16

  Active, not recruiting

  Phase 1, Phase 2

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers Start of enrollment: 2020 Feb 20

  Completed

  Phase 1

• A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis Start of enrollment: 2021 Aug 11

  Active, not recruiting

  Phase 1

• A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers Start of enrollment: 2020 Dec 23

  Completed

  Phase 1

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers Start of enrollment: 2017 Jun 01

  Completed

  Phase 1

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers Start of enrollment: 2017 Nov 16

  Completed

  Phase 1

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) Start of enrollment: 2022 Feb 01

  Active, not recruiting

  Phase 1, Phase 2

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants Start of enrollment: 2022 Jul 14

  Completed

  Phase 1

• A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002) Start of enrollment: 2005 Jul 01

  Completed

  Phase 1

• A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004) Start of enrollment: 2009 Mar 01

  Completed

  Phase 2

• A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1]) Start of enrollment: 2011 Dec 01

  Completed

  Phase 1

• Join now to see all